FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:1723 May 31, 2001 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

Edited by Carlo Greco and Michael J. Zelefsky. 484 pp., illustrated. Amsterdam, Harwood Academic, 2000. $115. ISBN 90-5702-482-9.

Prostate cancer is the most commonly diagnosed noncutaneous cancer and the second leading cause of death due to cancer among men living in the United States. During the year 2000, approximately 180,000 new cases were diagnosed in the United States, and the trend continued toward fewer new cases of advanced disease and more early-stage disease. This trend is attributable to the increased use of the serum level of prostate-specific antigen (PSA) as part of screening. Despite early detection, however, the effect on survival of screening with PSA is unknown and is the subject of randomized trials worldwide.

Along with the . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.